DIA

CALL FOR POSTER ABSTRACTS

SUBMISSION DEADLINE: THURSDAY, AUGUST 8

DIA/FDA Oligonucleotide-Based Therapeutics Conference

OCTOBER 28-30 | WASHINGTON, DC

CALL FOR POSTER ABSTRACTS

POSTER ABSTRACT SUBMISSION DETAILS AND GUIDELINES
SUBMISSION DEADLINE: THURSDAY, AUGUST 8

Poster Abstract Overview and Topics

Get involved! DIA and the Program Committee invite you to submit a poster abstract to be presented during the DIA/FDA Oligonucleotide-Based Therapeutics Conference, October 28-30. Posters describing research, best practices, or approaches related to oligonucleotides in areas of clinical, non-clinical, and CMC will be considered for acceptance.

Nonclinical Track

The nonclinical sessions are designed to provide updates and discussion on recent advancements in nonclinical development of oligonucleotide therapeutics. All mechanisms of RNA targeting therapeutics will be represented with a particular interest in delivery to non-hepatic tissues.

Clinical Development Track

These sessions will provide updates on the recent progress made with oligonucleotides in the clinic. Programs in various stages of development will highlight the challenges faced, lessons learned, and offer potential solutions and innovative ideas for clinical development of oligonucleotide therapeutics.

Chemistry, Manufacturing, and Controls (CMC) Track

The CMC track will cover a wide range of current oligonucleotide science and feature expert speakers from industry and regulatory agencies.

Poster submissions may include , but are not limited to, the following oligonucleotide-related topics:

- Assay Development and Optimization
- Clinical Pharmacology, including Oligonucleotide ADME
- Clinical Safety
- Formulations
- Hot Topics in Oligonucleotide Research
- Impurities
- Manufacturing
- Nonclinical Efficacy Models
- Toxicology, Including Updates in Oligo Toxicology (Clinical and Nonclinical)
- Novel Mechanisms for Intervention
- Novel Oligonucleotide Therapeutics
- Oligonucleotide Conjugation and Tissue Targeting
- Regulatory Affairs, Including Oligonucleotide Regulatory Guidance
- Oligonucleotide Therapeutics for:
  - Rare Diseases
  - Immuno-oncology
  - Metabolic and Cardiovascular Diseases
  - Neuromuscular Conditions
- Targeting and Delivery, Including Target Identification Screening Methods (Discovery)
- Translational Experience

We ask that all poster abstracts be noncommercial and scientific in nature, and not appear as a marketing opportunity. To submit a poster abstract, please follow the guidelines

Submit Your Abstract at **DIAglobal.org/Abstracts**

CALL FOR POSTER ABSTRACTS

SUBMISSION DEADLINE: AUGUST 8

GENERAL SUBMISSION REQUIREMENTS

(Please read the following instructions carefully; incorrect or incomplete abstracts will not be considered.)

- All submissions must be submitted online to DIAglobal.org/Abstracts
- Proposed abstract title must reflect the abstract content accurately and concisely.
- Poster abstracts must be noncommercial and scientific in nature, and may not be used as a marketing opportunity. Any mention of specific products and/or services must be limited to generic names, with no inclusion of brand names in any area of the poster, including poster titles and/or handouts. Logos and advertising may not appear anywhere on the poster.
- Poster abstracts must be original research and include appropriate empirical evidence.
- Poster abstracts must include data (i.e., research results and conclusion) for consideration. Preliminary/pilot data are acceptable.
- Poster abstracts submitted for presentation should not have been presented or published previously.
- A PDF version of the final poster will need to be submitted by requested date so that it may be viewable for download by attendees.

ONSITE REQUIREMENTS

- If an abstract is accepted, the primary author is required to pay the applicable forum registration fee, related expenses, and must be onsite at the conference during the designated poster session time. *An author may not present more than one poster.*
- Co-authors who would like to be present for your session must register as well. If none of the authors are able to attend the forum, we will withdraw your poster from the program.
- Presenters must organize and pay for all shipping arrangements for their poster materials. DIA will not ship or store any materials.
- Presenters must prepare a poster to fit a 4'h x 8'w poster board.

REQUIRED DOCUMENTATION FOR ALL ABSTRACTS

- **Participant Disclosure Information:** All abstract authors must disclose any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are submitting an abstract on behalf of the author, you (as the submitter) will not be ask to disclose. However, should the abstract be accepted, the author will be informed that he or she must complete and submit a Participant Disclosure in order to participate in the program.
- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted posters will be available on DIA's website for attendee download.

ACCEPTED POSTER PRESENTERS RECEIVE DISCOUNTED REGISTRATION RATES

The presenting author will receive a 10% discount* off their registration to the conference.

**The discount will be applied to the presenting author's registration category and cannot be combined with other offers.*

Poster Abstract Submission Deadline:
August 8

Notification:
Week of September 3

Final Poster PDF Due:
October 7

Poster Session:
Monday, October 28: Presented during Evening Reception 4:45-6:00PM

Poster Set Up:
October 28 (time to be determined)

Please submit all abstracts online at:
DIAglobal.org/Abstracts

Questions:
Contact Damisha White, Project Manager at Damisha.White@DIAglobal.org

SUBMISSION GUIDELINES

The following information will be requested at the time of submission. ***DIAglobal.org/Abstracts***

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Submitter or Author Information

Prefix:

First Name:

Middle Name:

Last Name:

Name Suffix:

Degrees:

Job Title:

Company:

Country:

Address Line:

City:

State/Province:

Zip/Postal Code:

Phone:

Email:

NOTE: If you are submitting on behalf of the author, you are considered the SUBMITTER and will need to complete the required information for yourself AND ALSO for the AUTHOR. Submitters will be the contact for author regarding the status of the abstract.

Abstract Title (maximum 125 characters, including spaces)
Titles should briefly describe the focus of the abstract as well as accurately reflect the content of the poster.

Primary interest Area
Select the interest area that best relates to your abstract

Keyword (Maximum 100 characters including spaces)
One or more keywords are to be provided to highlight your abstract. Examples of keywords: Personalized Medicine, Health Technology Assessment, and Clinical Trial Agreements.

Objective (Maximum 300 characters including spaces)
A one sentence statement of the objective of the abstract.

Method (Maximum 300 characters including spaces)
When, where, and how was the study done? What materials were used or who was included in the study?

Results (Maximum 2000 characters including spaces)
What quantitative data was collected? What answer was found to the research question? What did the study find? Was the tested hypothesis true?

Conclusion (Maximum 2000 characters including spaces)
State what can be concluded from the study and its implications.

Abstracts will be reviewed and authors will be notified of results the week of September 3.